TOP NEWS: AstraZeneca prostate cancer drug Lynparza backed in China

(Alliance News) - AstraZeneca PLC said Thursday that its Lynparza drug has been approved in China ...

Alliance News 24 June, 2021 | 8:36AM
Email Form Facebook Twitter LinkedIn RSS

(Alliance News) - AstraZeneca PLC said Thursday that its Lynparza drug has been approved in China for the treatment of a form of castration-resistant prostate cancer.

China's National Medical Products Administration granted approval to treat adult patients with germline or somatic BRCA-mutated metastatic prostate cancer who have progressed following treatment that included a new hormonal agent.

The approval was based on an earlier trial which found the use of Lynparza led to a "substantial improvement" in radiographic progression-free survival and overall survival compared to other treatments currently used. The trial showed Lynparza reduced the risk of disease progression or death by 78%.

"This approval begins a new era of precision medicine for patients in China with advanced prostate cancer who have historically had a poor prognosis and few treatment options," said Dave Fredrickson, Executive Vice President of Oncology.

"Lynparza more than tripled radiographic progression-free survival in the PROfound trial and is the only PARP inhibitor to show an overall survival benefit compared to treatment with new hormonal agents for men with BRCA-mutated metastatic castration-resistant prostate cancer."

Lynparza has been co-developed by AstraZeneca and New Jersey, US-based pharmaceutical drugs firm Merck & Co Inc.

Shares in AstraZeneca were up 0.2% in London on Thursday morning at 8,335.00 pence each.

By Will Paige; willpaige@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

Email Form Facebook Twitter LinkedIn RSS

Securities Mentioned in Article

Security Name Price Change (%) Morningstar
Rating
GlaxoSmithKline PLC 1,416.00 GBX 0.45
Merck & Co Inc 77.54 USD 1.32

About Author

Alliance News

Alliance News provides Morningstar with continuously updating coverage of news affecting listed companies.

Audience Confirmation


By clicking 'accept' I acknowledge that this website uses cookies and other technologies to tailor my experience and understand how I and other visitors use our site. See 'Cookie Consent' for more detail.

  • Other Morningstar Websites
© Copyright 2021 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Cookies       Modern Slavery Statement